We are live on ! Find out more
ANGO icon

AngioDynamics

174 hedge funds and large institutions have $810M invested in AngioDynamics in 2018 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 60 increasing their positions, 56 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

235% more call options, than puts

Call options by funds: $295K | Put options by funds: $88K

92% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 13

29% more capital invested

Capital invested by funds: $626M → $810M (+$184M)

6% more funds holding

Funds holding: 164174 (+10)

7% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 56

0.22% more ownership

Funds ownership: 98.78%99.01% (+0.22%)

Holders
174
Holders Change
+10
Holders Change %
+6.1%
% of All Funds
3.98%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
25
Increased
60
Reduced
56
Closed
13
Calls
$295K
Puts
$88K
Net Calls
+$207K
Net Calls Change
+$665K

ANGO Hedge Fund Activity: Q2 2018 in Review

174 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in AngioDynamics (ANGO) for Q2 2018, worth a combined $810M — up 29% from $626M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ANGO positions and 13 closed out — a net gain of 12 holders — while 60 added to existing stakes and 56 trimmed.

The largest buyer was Lazard Asset Management, opening a new position worth an estimated $12.4M. The largest seller was Broadfin Capital, exiting entirely with an estimated $15.7M sold.

  • 174 institutional investors held AngioDynamics (ANGO) as of Q2 2018, up from 164 in Q1 2018.
  • Funds reported $810M of AngioDynamics stock for Q2 2018, up 29% quarter-over-quarter.
  • 25 funds opened new AngioDynamics positions in Q2 2018 and 13 closed out, a net change of +12 holders.
  • The largest AngioDynamics buyer in Q2 2018 was Lazard Asset Management, an estimated $12.4M added.
  • The largest AngioDynamics seller in Q2 2018 was Broadfin Capital, an estimated $15.7M sold.

Based on aggregated 13F filings for Q2 2018.